InC01
Glioblastoma
Pre-clinicalActive
Key Facts
About InCephalo Therapeutics
InCephalo Therapeutics is a private, preclinical-stage biotech based in Basel, Switzerland, developing a novel class of biologics for central nervous system (CNS) diseases. Its core innovation, the C-Lock™ platform, engineers proteins to be retained exclusively within the brain compartment, enabling high-dose, localized immune activation without the severe systemic side effects that have plagued previous approaches. With lead asset InC01 targeting glioblastoma and supported by strong preclinical data and EMA Orphan Drug Designation, the company is positioned to address a critical unmet need with a potentially transformative treatment modality.
View full company profileOther Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |
| BEA-17 | Beactica Therapeutics | Pre-clinical |